中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

已选(0)清除 条数/页：   排序方式：
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021
作者:  Zhang, Xiangyu;  Zeng, Liang;  Li, Yizhi;  Xu, Qinqin;  Yang, Haiyan;  Lizaso, Analyn;  Mao, Xinru;  Jin, Ren'an;  Zeng, Yu;  Li, Qinglin;  Wang, Jianbo;  Li, Yang;  Zhang, Yongchang;  Yang, Nong
收藏  |  浏览/下载：56/0  |  提交时间：2021/03/15
Anlotinib  Immunotherapy  Programmed death 1 inhibitor  Lung cancer  
Prevalence and clinical significance of pathogenic germline BRCA1 2 mutations in Chinese non-small cell lung cancer patients 期刊论文
Cancer Biology & Medicine, 2019, 卷号: 16
作者:  Hu Xingsheng;  Yang Dongyong;  Li Yalun;  Li Li;  Wang Yan;  Chen Peng;  Xu Song;  Pu Xingxiang;  Zhu Wei;  Deng Pengbo;  Yen Junyi;  Zhang Hanhan;  Lizaso Analyn;  Liu Hao;  Mao Xinru;  Huang Hai;  Chu Qian;  Hu Chengping
收藏  |  浏览/下载：68/0  |  提交时间：2020/12/28
SUSCEPTIBILITY LOCUS  PROSTATE-CANCER  OVARIAN-CANCER  BREAST  RISK  MULTICENTER  EXPRESSION  INHIBITORS  VARIANTS  CARRIERS  Germline BRCA mutations  non-small cell lung cancer  prevalence  BRCA1  BRCA2